CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 Polymorphisms in Patients With Bosentan-Induced Liver Toxicity

被引：13

作者：

Roustit, M. ^{[1
,2
]}

Fonrose, X. ^{[3
]}

Montani, D. ^{[4
,5
]}

Girerd, B. ^{[4
,5
]}

Stanke-Labesque, F. ^{[2
,3
]}

Gonnet, N. ^{[2
]}

Humbert, M. ^{[4
,5
]}

Cracowski, J-L ^{[1
,2
]}

机构：

[1] Univ Grenoble Alpes, INSERM UMR HP2 1042, Grenoble, France

[2] Grenoble Univ Hosp, Clin Pharmacol Unit, INSERM CIC1406, Grenoble, France

[3] Grenoble Univ Hosp, Lab Pharmacol, Grenoble, France

[4] Univ Paris Sud, AP HP, Ctr Natl Reference Hypertens Pulm Severe,DHU, Thorax Innovat TORINO,Hop Bicetre,Serv Pneumol, F-94275 Le Kremlin Bicetre, France

[5] Ctr Chirurg Marie Lannelongue, LabEx LERMIT, INSERM UMRS 999, Le Plessis Robinson, France

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷 / 06期

关键词：

MECHANISM; INHIBITION; EXPORT;

D O I：

10.1038/clpt.2014.42

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Bosentan is an endothelin receptor antagonist used as a first-line treatment in pulmonary arterial hypertension (PAH). Its main adverse effect is a dose-dependent liver toxicity. CYP2C9*2 has recently been shown to be associated with hepatotoxicity in PAH patients. We conducted a nested case-control study to further explore the relationship between functional polymorphisms of gene products involved in bosentan pharmacokinetics (OATP1B1, OATP1B3, and CYP2C9) or hepatobiliary transporters affected by bosentan (ABCB11) and bosentan-induced liver toxicity.

引用

页码：583 / 585

页数：3

共 50 条

[1] Influence of CYP2C9 and SLCO1B1 genotype on bosentan-induced liver toxicity
Roustit, M.
Fonrose, X.
Montani, D.
Girerd, B.
Gonnet, N.
Lunardi, J.
Stanke, F.
Humbert, M.
Cracowski, J. L.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 81 - 82
[2] SLCO1B1, SLCO2B1, and SLCO1B3 Polymorphisms and Susceptibility to Bladder Cancer Risk
Hoai Thi Thu Bui
Fujimoto, Naohiro
Kubo, Tatsuhiko
Inatomi, Hisato
Matsumoto, Tetsuro
CANCER INVESTIGATION, 2014, 32 (06) : 256 - 261
[3] Influence of Genomic Ancestry on the Distribution of SLCO1B1, SLCO1B3 and ABCB1 Gene Polymorphisms among Brazilians
Sortica, Vinicius de A.
Ojopi, Elida B.
Genro, Julia P.
Callegari-Jacques, Sidia
Ribeiro-dos-Santos, Andrea
de Moraes, Manoel Odorico
Romano-Silva, Marco A.
Pena, Sergio D. J.
Suarez-Kurtz, Guilherme
Hutz, Mara H.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 110 (05) : 460 - 468
[4] SLCO1B1 and SLCO1B3 genetic mutations in Taiwanese patients with Rotor syndrome
Cheng, Ya-Yuan
Chang, Kai -Chi
Chen, Pei -Lung
Yeung, Chun-Yan
Liou, Bang -Yu
Chen, Huey -Ling
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2023, 122 (07) : 648 - 652
[5] Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
Song, Gonjin
Chung, Jee-Eun
Yee, Jeong
Lee, Kyung-Eun
Park, Kyungsoo
Gwak, Hye-Sun
JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09):
[6] Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report
Dagli-Hernandez, Carolina
Costa de Freitas, Renata Caroline
Rodrigues Marcal, Elisangela da Silva
Goncalves, Rodrigo Marques
Faludi, Andre Arpad
Borges, Jessica Bassani
Bastos, Gisele Medeiros
Los, Bruna
Mori, Augusto Akira
Bortolin, Raul Hernandes
Ferreira, Glaucio Monteiro
de Oliveira, Victor Fernandes
Crespo Hirata, Thiago Dominguez
Hirata, Mario Hiroyuki
Crespo Hirata, Rosario Dominguez
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (01)
[7] UGT1A1, SLCO1B1, and SLCO1B3 polymorphisms vs. neonatal hyperbilirubinemia: is there an association?
Laura Alencastro de Azevedo
Themis Reverbel da Silveira
Clarissa Gutierrez Carvalho
Simone Martins de Castro
Roberto Giugliani
Ursula Matte
Pediatric Research, 2012, 72 : 169 - 173
[8] UGT1A1, SLCO1B1, and SLCO1B3 polymorphisms vs. neonatal hyperbilirubinemia: is there an association?
de Azevedo, Laura Alencastro
da Silveire, Themis Reverbel
Carvalho, Clarissa Gutierrez
de Castro, Simone Martins
Giugliani, Roberto
Matte, Ursula
PEDIATRIC RESEARCH, 2012, 72 (02) : 169 - 173
[9] Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups
Namgoong, Suhg
Cheong, Hyun Sub
Kim, Ji On
Kim, Lyoung Hyo
Na, Han Sung
Koh, In Song
Chung, Myeon Woo
Shin, Hyoung Doo
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2015, 40 (03) : 692 - 697
[10] Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers
Yu Cheng
Guo Wang
Wei Zhang
Lan Fan
Yao Chen
Hong-Hao Zhou
European Journal of Clinical Pharmacology, 2013, 69 : 407 - 413

← 1 2 3 4 5 →